Entity Details
Primary name |
AGAL_HUMAN |
Entity type |
UniProt |
Source |
Source Link |
Details
Accession | P06280 |
EntryName | AGAL_HUMAN |
FullName | Alpha-galactosidase A |
TaxID | 9606 |
Evidence | evidence at protein level |
Length | 429 |
SequenceStatus | complete |
DateCreated | 1988-01-01 |
DateModified | 2021-06-02 |
Subcellular Location
Show/Hide Table
Subcellular Location |
Lysosome |
Domains
Show/Hide Table
Domain | Name | Category | Type |
IPR000111 | Glycoside hydrolase family 27/36, conserved site | Site | Conserved site |
IPR002241 | Glycoside hydrolase, family 27 | Family | Family |
IPR013780 | Glycosyl hydrolase, all-beta | Family | Homologous superfamily |
IPR013785 | Aldolase-type TIM barrel | Family | Homologous superfamily |
IPR017853 | Glycoside hydrolase superfamily | Family | Homologous superfamily |
IPR035373 | Alpha galactosidase A, C-terminal beta-sandwich domain | Domain | Domain |
Diseases
Show/Hide Table
Disease ID | Source | Name | Description |
301500 | OMIM | Fabry disease (FD) | Rare X-linked sphingolipidosis disease where glycolipid accumulates in many tissues. The disease consists of an inborn error of glycosphingolipid catabolism. FD patients show systemic accumulation of globotriaosylceramide (Gb3) and related glycosphingolipids in the plasma and cellular lysosomes throughout the body. Clinical recognition in males results from characteristic skin lesions (angiokeratomas) over the lower trunk. Patients may show ocular deposits, febrile episodes, and burning pain in the extremities. Death results from renal failure, cardiac or cerebral complications of hypertension or other vascular disease. Heterozygous females may exhibit the disorder in an attenuated form, they are more likely to show corneal opacities. The disease is caused by variants affecting the gene represented in this entry. |
Drugs
Show/Hide Table
Drug | Name | Source | Type |
DB05018 | Migalastat | Drugbank | small molecule |
Interactions
7 interactions